Richard H. Ko

817 total citations
30 papers, 576 citations indexed

About

Richard H. Ko is a scholar working on Hematology, Internal Medicine and Molecular Biology. According to data from OpenAlex, Richard H. Ko has authored 30 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 7 papers in Internal Medicine and 5 papers in Molecular Biology. Recurrent topics in Richard H. Ko's work include Hemophilia Treatment and Research (12 papers), Blood Coagulation and Thrombosis Mechanisms (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Richard H. Ko is often cited by papers focused on Hemophilia Treatment and Research (12 papers), Blood Coagulation and Thrombosis Mechanisms (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Richard H. Ko collaborates with scholars based in United States, Switzerland and United Kingdom. Richard H. Ko's co-authors include Lingyun Ji, Guy Young, Paul S. Gaynon, Nita L. Seibel, Elena Eckroth, Mignon L. Loh, Richard Sposto, Bruce Bostrom, Phillip Barnette and Elizabeth A. Raetz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Richard H. Ko

30 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard H. Ko United States	12	364	223	112	108	82	30	576
Kaie Pruunsild Norway	10	215 0.6×	512 2.3×	108 1.0×	401 3.7×	73 0.9×	14	683
Alaa Elhaddad Egypt	15	233 0.6×	111 0.5×	142 1.3×	84 0.8×	95 1.2×	65	518
Saïd Benchekroun Morocco	13	117 0.3×	165 0.7×	120 1.1×	145 1.3×	97 1.2×	61	480
Sunday Ocheni Nigeria	15	252 0.7×	69 0.3×	176 1.6×	57 0.5×	53 0.6×	52	531
G. Fleischhack Germany	11	73 0.2×	104 0.5×	113 1.0×	46 0.4×	73 0.9×	18	396
Mohamed Elemary Canada	13	454 1.2×	114 0.5×	117 1.0×	29 0.3×	31 0.4×	33	578
Damir Nemet Croatia	13	248 0.7×	65 0.3×	105 0.9×	37 0.3×	107 1.3×	53	474
Giuliana Farina Italy	7	95 0.3×	91 0.4×	26 0.2×	50 0.5×	87 1.1×	16	372
José Mariz Portugal	11	110 0.3×	51 0.2×	67 0.6×	14 0.1×	89 1.1×	41	362
Saad Al‐Ismail United Kingdom	13	99 0.3×	55 0.2×	100 0.9×	81 0.8×	32 0.4×	29	355

Countries citing papers authored by Richard H. Ko

Since Specialization

Citations

This map shows the geographic impact of Richard H. Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard H. Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard H. Ko more than expected).

Fields of papers citing papers by Richard H. Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard H. Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard H. Ko. The network helps show where Richard H. Ko may publish in the future.

Co-authorship network of co-authors of Richard H. Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Richard H. Ko. A scholar is included among the top collaborators of Richard H. Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard H. Ko. Richard H. Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davids, Matthew S., John M. Burke, Vivek S. Chopra, et al.. (2024). BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia. Blood. 144(Supplement 1). 3257.2–3257.2. 1 indexed citations

Pipe, Steven W., Miranda Minhas, Michaela Lehle, et al.. (2023). Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. Research and Practice in Thrombosis and Haemostasis. 7(2). 100077–100077. 7 indexed citations

Howard, Monet, et al.. (2021). Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies. Blood. 138(Supplement 1). 3186–3186. 15 indexed citations

Pipe, Steven W., Rebecca Kruse‐Jarres, Johnny Mahlangu, et al.. (2020). Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis. 19. 21–31. 9 indexed citations

Callaghan, Michael U., Benjamin Trzaskoma, Richard H. Ko, et al.. (2019). Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience. Blood. 134(Supplement_1). 2395–2395. 5 indexed citations

Raimundo, Karina, et al.. (2018). Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval. Blood. 132(Supplement 1). 5020–5020. 1 indexed citations

Ji, Lingyun, Richard H. Ko, Deepa Bhojwani, et al.. (2018). Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thrombosis Research. 165. 44–50. 20 indexed citations

Kruse‐Jarres, Rebecca, Michael U. Callaghan, Stacy E. Croteau, et al.. (2017). Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood. 130(Suppl_1). 89–89. 43 indexed citations

Ko, Richard H. & Courtney D. Thornburg. (2017). Venous Thromboembolism in Children with Cancer and Blood Disorders. Frontiers in Pediatrics. 5. 12–12. 21 indexed citations

10.

Jaffray, Julie, Guy Young, & Richard H. Ko. (2016). The bleeding newborn: A review of presentation, diagnosis, and management. Seminars in Fetal and Neonatal Medicine. 21(1). 44–49. 11 indexed citations

11.

Kitchen, Steve, Kenneth D. Friedman, Daniel P. Hart, et al.. (2016). A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assays. Journal of Thrombosis and Haemostasis. 14(4). 757–764. 29 indexed citations

12.

Ko, Richard H., Tamekia L. Jones, David Radvinsky, et al.. (2015). Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 121(23). 4205–4211. 23 indexed citations

13.

Ko, Richard H., et al.. (2014). FondaKIDS II: Long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thrombosis Research. 134(3). 643–647. 23 indexed citations

14.

Ko, Richard H., Lingyun Ji, & Guy Young. (2013). A novel approach for detecting hypercoagulability utilizing thromboelastography. Thrombosis Research. 131(4). 352–356. 14 indexed citations

15.

Ko, Richard H. & Guy Young. (2012). Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Review of Clinical Pharmacology. 5(4). 389–396. 6 indexed citations

16.

Gorman, Matthew F., Lingyun Ji, Richard H. Ko, et al.. (2010). Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study. Pediatric Blood & Cancer. 55(3). 421–429. 83 indexed citations

17.

Ko, Richard H., Lingyun Ji, Phillip Barnette, et al.. (2009). Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study. Journal of Clinical Oncology. 28(4). 648–654. 191 indexed citations

18.

Tam, Jennifer, Cathi Dennehy, Richard H. Ko, & Candy Tsourounis. (2006). Analysis of Ephedra-Free Labeled Dietary Supplements Sold in the San Francisco Bay Area in 2003. Journal of Herbal Pharmacotherapy. 6(2). 1–19. 1 indexed citations

19.

Sattler, Fred R., Richard H. Ko, Diana Antoniskis, et al.. (1991). Acetaminophen Does Not Impair Clearance of Zidovudine. Annals of Internal Medicine. 114(11). 937–940. 15 indexed citations

20.

Hu, Eddie, Richard H. Ko, Robert T. Koda, et al.. (1990). Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 26(5). 359–364. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact